Generation of Dose–Response Curves and Improved IC50s for PARP Inhibitor Nanoformulations
- 2 February 2017
- book chapter
- Published by Springer Nature
- Vol. 1530, 337-342
Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors that target DNA damage repair pathways in cancer cells are increasingly attractive for treating several cancers. Determining the half maximal inhibitory concentration (IC50) of these molecular inhibitors in cell lines is crucial for further dosing for in vivo experiments. Typically these in vitro assays are conducted for 24–72 h; however, PARP inhibitors exhibit cytotoxicity based on the inability to repair DNA damage and thus the accumulation of deleterious mutations takes place over longer times. Therefore, in order to determine a relevant dose response, the time frame of the assay must be modified to account for the time required for the cells to exhibit effects from the treatment. Here, we describe two techniques for generating both short- and long-term dose–response curves for both free PARP inhibitors and nanoparticle formulations of these drugs.Keywords
This publication has 10 references indexed in Scilit:
- Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?Cancer Research, 2014
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair DeficiencyClinical Cancer Research, 2013
- MTT assay for cell viability: Intracellular localization of the formazan product is in lipid dropletsActa Histochemica, 2012
- PARP inhibition: PARP1 and beyondNature Reviews Cancer, 2010
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break RepairJournal of Clinical Oncology, 2008
- Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular DeliveryPharmaceutical Research, 2007
- Clonogenic assay of cells in vitroNature Protocols, 2006
- New approaches to molecular cancer therapeuticsNature Chemical Biology, 2006
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- A gene expression database for the molecular pharmacology of cancerNature Genetics, 2000